Comparison of Immune Response in Pneumococcal Pneumonia and After Vaccination
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Pneumococcal Pneumonia
- Sponsor
- Helsinki University Central Hospital
- Enrollment
- 42
- Locations
- 4
- Primary Endpoint
- Expression of homing receptors on circulating plasmablasts in Pnc pneumonia and after vaccination
- Status
- Completed
- Last Updated
- 14 years ago
Overview
Brief Summary
Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)
Detailed Description
Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study compares the homing profiles of Pnc-specific plasmablasts in 15 patients with pneumonia and in 15 volunteers receiving Pnc polysaccharide vaccine (PPV) and 12 volunteers receiving Pnc conjugate vaccine (PCV)
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males and females ≥ 18 and \<65 years of age.
- •General good health.
- •Written informed consent.
- •No previous vaccination against Pnc
- •No previous history of Pnc pneumonia
- •In pneumonia: Diagnosis of Pnc pneumonia within a week
Exclusion Criteria
- •\< 18 years, ≥65 of age.
- •In vaccinees: Acute disease at the time of enrollment.
- •Pregnancy or lactation.
- •Known immunodeficiency or immune suppressive treatment.
- •Any chronic illness that might interfere with the immune response
- •Alcohol or drug abuse
- •Any clinically significant history of known or suspected anaphylaxis or hypersensitivity (based on the investigator's judgement).
Outcomes
Primary Outcomes
Expression of homing receptors on circulating plasmablasts in Pnc pneumonia and after vaccination
Time Frame: Day 0 and Day 7-10
HR on circulating Pnc-specific plasmablasts are determined in patients with pneumonia on day 7-10, in vaccinees on days 0 and 7